article thumbnail

Pfizer hires Citi analyst Andrew Baum to manage portfolio strategy, business development

Fierce Pharma

“Our next question will come from Andrew Baum with Citi.” | Citi analyst Andrew Baum, after covering Pfizer for more than a decade, will join the Big Pharma company as chief strategy and innovation officer. In the role, he'll oversee the drugmaker's portfolio management and business development activities.

article thumbnail

How Are Biopharma Companies Evaluating Partnerships in the Rare Disease Space?

Camargo

Thomas Kassberg, Chief Business Officer, Ultragenyx. The amount of interest and investment in rare diseases and orphan drugs has grown tremendously in recent years, leading to continuous innovation in a space that was once largely overlooked.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Merck confirms $11.5bn Acceleron takeover deal

pharmaphorum

.” It also said that “strategic business development” is a top priority for the company at the moment, reflecting a longstanding concern that it has become over-reliant on Keytruda and needs to diversify.

Sales 117
article thumbnail

Leading pharmaceutical solid dose (commercial dose) manufacturing companies in contract marketing

Pharmaceutical Technology

Contract development and manufacturing organisations are increasingly becoming an important part of oral solid dose drug development and manufacturing process for many small, medium as well as large pharma companies.

article thumbnail

Synthetic control arms in clinical trials: Making it happen

pharmaphorum

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials. But what does it take to implement these innovations? Mark holds a PhD in biomedicine, and an MSc in biostatistics.

article thumbnail

Patient involvement in trial design: looking to the future

pharmaphorum

As moderator Gareth Powell – business development officer, patient engagement and clinical development service project lead at the NIHR – noted, the Institute has seen fantastic feedback from patients on the increased use of virtual engagement over the course of pandemic.

Trials 132
article thumbnail

Why pharma isn’t yet achieving digital excellence, and how it can get there

pharmaphorum

This includes using its technology as a ‘ digital excellence cloud ’ to harness data, content management, insights and execution while also offering business consulting services to help pharma companies with strategy, processes, and change management.

Sales 131